Compare Pfizer Inc (PFE) vs Sprott Uranium Miners ETF (URNM) Price & Performance

Pfizer (PFE) trades at $24.75, down 1.2% on the day, with a neutral technical outlook. The company maintains strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $0.75 beating expectations of $0.722. Pfizer demonstrates robust profitability with a 73.51% gross margin and 11.83% net income margin, though revenue has moderated from pandemic peaks. Recent news highlights the company's focus on AI drug discovery and pipeline development.

Pfizer presents a value opportunity trading below analyst consensus target of $28.25, with 38% of analysts rating it Buy. The stock offers a solid dividend yield with recent $0.43 payments. Key risks include patent expirations and revenue normalization post-COVID, while catalysts include obesity and oncology pipeline developments in 2026.

URNM trades at $48.25 with minimal daily movement (+0.06%). The ETF shows bearish technical signals with moving averages indicating selling pressure, though RSI suggests potential oversold conditions. Recent news highlights uranium's role in AI power demand, with nuclear energy positioned as a solution to data center electricity needs. The fund has gained significant attention for its pure-play uranium miner exposure versus broader nuclear ETFs.

The uranium sector faces a favorable long-term outlook with projected nuclear demand tripling by 2050, though current technical weakness and concentration risks in mining companies present near-term challenges. URNM offers leveraged exposure to uranium price movements but remains vulnerable to sector volatility and supply chain constraints.